Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;21(6):594-608.
doi: 10.6004/jnccn.2023.0031.

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

William J Gradishar  1 , Meena S Moran  2 , Jame Abraham  3 , Vandana Abramson  4 , Rebecca Aft  5 , Doreen Agnese  6 , Kimberly H Allison  7 , Bethany Anderson  8 , Harold J Burstein  9 , Helen Chew  10 , Chau Dang  11 , Anthony D Elias  12 , Sharon H Giordano  13 , Matthew P Goetz  14 , Lori J Goldstein  15 , Sara A Hurvitz  16 , Rachel C Jankowitz  17 , Sara H Javid  18 , Jairam Krishnamurthy  19 , A Marilyn Leitch  20 , Janice Lyons  3 , Joanne Mortimer  21 , Sameer A Patel  15 , Lori J Pierce  22 , Laura H Rosenberger  23 , Hope S Rugo  24 , Bryan Schneider  25 , Mary Lou Smith  26 , Hatem Soliman  27 , Erica M Stringer-Reasor  28 , Melinda L Telli  7 , Mei Wei  29 , Kari B Wisinski  8 , Jessica S Young  30 , Kay Yeung  31 , Mary A Dwyer  32 , Rashmi Kumar  32
Affiliations

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

William J Gradishar et al. J Natl Compr Canc Netw. 2023 Jun.

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly. The therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number of treatment options, if one option fails, there is usually another line of therapy available, providing meaningful improvements in survival. This NCCN Guidelines Insights report focuses on recent updates specific to systemic therapy recommendations for patients with stage IV (M1) disease.

PubMed Disclaimer

LinkOut - more resources